US Stock MarketDetailed Quotes
NLSP NLS Pharmaceutics
- 0.1355
- +0.0031+2.34%
Trading Apr 26 13:29 ET
5.88MMarket Cap-271P/E (TTM)
0.1450High0.1225Low216.85KVolume0.1230Open0.1324Pre Close28.68KTurnover0.86%Turnover RatioLossP/E (Static)43.39MShares1.530052wk High-1.37P/B3.41MFloat Cap0.113052wk Low--Dividend TTM25.16MShs Float7.3500Historical High--Div YieldTTM16.99%Amplitude0.1130Historical Low0.1320Avg Price1Lot Size
NLS Pharmaceutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | (FY)Dec 31, 2018 | (FY)Dec 31, 2017 | |
|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||
| Gross profit | ||||||
| Operating expense | 30.54%15.48M | 415.82%11.86M | -45.21%2.3M | 21.69%4.2M | -40.19%3.45M | 5.77M |
| Selling and administrative expenses | 9.50%6.51M | 170.08%5.94M | -33.32%2.2M | 20.39%3.3M | 90.05%2.74M | --1.44M |
| -General and administrative expense | 9.50%6.51M | 170.08%5.94M | -33.32%2.2M | 20.39%3.3M | 90.05%2.74M | --1.44M |
| Research and development costs | 51.65%8.98M | 5,844.42%5.92M | -88.91%99.58K | 26.72%897.79K | -83.62%708.46K | --4.32M |
| Operating profit | -30.54%-15.48M | -415.82%-11.86M | 45.21%-2.3M | -21.69%-4.2M | 40.19%-3.45M | -5.77M |
| Net non-operating interest income expense | -48.04%-100.87K | 70.85%-68.13K | 71.49%-233.7K | 24.43%-819.71K | -21.82%-1.08M | -890.4K |
| Non-operating interest expense | 48.04%100.87K | -70.85%68.13K | -71.49%233.7K | -24.43%819.71K | 21.82%1.08M | --890.4K |
| Other net income (expense) | -5,167.27%-912.45K | 94.72%-17.32K | 23.71%-328.37K | 29.81%-430.4K | -613.2K | |
| Special income (charges) | ---922.5K | --0 | --0 | 42.00%-364.95K | ---629.23K | --0 |
| -Less:Other special charges | --922.5K | ---- | ---- | -42.00%364.95K | --629.23K | ---- |
| Other non- operating income (expenses) | 157.99%10.05K | 94.72%-17.32K | -401.74%-328.37K | -508.14%-65.45K | --16.04K | ---- |
| Income before tax | -38.08%-16.5M | -317.49%-11.95M | 47.47%-2.86M | -5.84%-5.45M | 22.69%-5.15M | -6.66M |
| Income tax | ||||||
| Net income | -38.08%-16.5M | -317.49%-11.95M | 47.47%-2.86M | -5.84%-5.45M | 22.69%-5.15M | -6.66M |
| Net income continuous Operations | -38.08%-16.5M | -317.49%-11.95M | 47.47%-2.86M | -5.84%-5.45M | 22.69%-5.15M | ---6.66M |
| Minority interest income | ||||||
| Net income attributable to the parent company | -38.08%-16.5M | -317.49%-11.95M | 47.47%-2.86M | -5.84%-5.45M | 22.69%-5.15M | -6.66M |
| Preferred stock dividends | ||||||
| Other preferred stock dividends | ||||||
| Net income attributable to common stockholders | -38.08%-16.5M | -317.49%-11.95M | 47.47%-2.86M | -5.84%-5.45M | 22.69%-5.15M | -6.66M |
| Basic earnings per share | 16.00%-0.84 | -270.32%-1 | 41.60%-0.27 | -5.84%-0.4624 | 22.69%-0.4369 | -0.5652 |
| Diluted earnings per share | 16.00%-0.84 | -270.32%-1 | 41.60%-0.27 | -5.84%-0.4624 | 22.69%-0.4369 | -0.5652 |
| Dividend per share | ||||||
| Currency Unit | USD | USD | USD | USD | USD | USD |
| Audit Opinions | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg